First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center
暂无分享,去创建一个
[1] C. Yim,et al. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report , 2019, BMC Nephrology.
[2] I. Chirivella,et al. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma , 2018, BMC Pharmacology and Toxicology.
[3] Myung Soo Kim,et al. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib , 2018, Journal of Korean medical science.
[4] N. Vogelzang,et al. Predictors of Long‐Term Response With Pazopanib in Patients With Advanced Renal‐Cell Carcinoma , 2018, Clinical genitourinary cancer.
[5] R. Motzer,et al. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial , 2018, Journal of Hematology & Oncology.
[6] K. Lakshmaiah,et al. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience. , 2017, Indian journal of cancer.
[7] A. Kapoor,et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[8] G. Ciliberto,et al. Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale” , 2016, Front. Pharmacol..
[9] S. Menon,et al. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data. , 2016, Indian journal of cancer.
[10] T. Choueiri,et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2016, European journal of cancer.
[11] G. Ciliberto,et al. Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale” , 2016, Front. Pharmacol..
[12] S. Park,et al. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma , 2016, BMC Urology.
[13] T. Bathala,et al. Outcomes of unselected patients with metastatic clear‐cell renal cell carcinoma treated with first‐line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience , 2016, BJU international.
[14] J. Beaumont,et al. Pazopanib in the treatment of advanced renal cell carcinoma , 2016, Therapeutic advances in urology.
[15] R. Kurzrock,et al. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art , 2014, Cancer and Metastasis Reviews.
[16] M. Harrison,et al. Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma , 2010, Clinical Medicine Insights. Oncology.